loading page

Efficacy and perceived satisfaction of 3-year SLIT in children with allergic rhinitis and asthma: A pilot study in real-life .
  • +5
  • Sara Manti,
  • Giulia Maria Diletta Tropea,
  • Caterina Ledda,
  • Giuseppe Fabio Parisi,
  • Maria Papale,
  • Enrico Compalati,
  • Franco Frati,
  • Salvatore Leonardi
Sara Manti
Universita degli Studi di Catania Scuola Facolta di Medicina

Corresponding Author:saramanti@hotmail.it

Author Profile
Giulia Maria Diletta Tropea
Universita degli Studi di Catania Scuola Facolta di Medicina
Author Profile
Caterina Ledda
Universita degli Studi di Catania Scuola Facolta di Medicina
Author Profile
Giuseppe Fabio Parisi
Universita degli Studi di Catania Scuola Facolta di Medicina
Author Profile
Maria Papale
Universita degli Studi di Catania Scuola Facolta di Medicina
Author Profile
Enrico Compalati
Lofarma SpA
Author Profile
Franco Frati
Lofarma SpA
Author Profile
Salvatore Leonardi
Universita degli Studi di Catania Scuola Facolta di Medicina
Author Profile

Abstract

Background. Despite the presence of robust evidence, very sparse data are available on the efficacy of allergen immunotherapy (AIT) on selected patients in  real-life. Moreover, the obtained data does not ever fit with the general population; thus, the translation and the use of data obtained from randomized clinical trials (RCTs) in  real-practice can be questionable. Accordingly, we aimed to evaluate in  real-life efficacy and perceived satisfaction of 3-year sublingual immunotherapy (SLIT) in a pediatric population with with allergic rhinitis and/or asthma. Methods. A pilot, monocenter, retrospective cohort,  real-life study was performed. 153 children who fulfilled the criteria for allergic rhinitis and asthma and mono- or poly-sensitized were enrolled. A standardized questionnaire on perceived efficacy, rescue medication, disease control, number of exacerbations, quality of life, and perceived satisfaction was administered to each patient. Results. 70 patients (49 males, 21 females; mean age, 14.3±1.9 years) were included in the final analysis. All 70 patients received SLIT for up to three years, with 100% treatment adherence throughout the study duration. Significant improvement in symptoms and quality of life was reported (p<0.01). A significant decrease in disease severity, rescue medication use, and sleep disturbances was reported (p<0.01). A significant improvement was also recorded in school performance (p<0.01).  60/70 (85.7%) of all enrolled patients declared themselves  very  satisfied, 6/70 (8.57%)  much satisfied, and 4/60 (5.71%)  satisfiedConclusions. We firstly showed the efficacy and perceived satisfaction of 3-year SLIT in a paediatric population, with 100% treatment adherence throughout the study duration, in  real-life.